Evidence review
Oral vs Injectable Peptides: What Changes
One molecule, two routes, one label — and roughly 73 times the milligrams per week. What the gut does to a peptide, and what it costs to get past it.
The problem a peptide has with your gut
Your digestive system exists to break proteins into amino acids. A peptide is a short chain of amino acids. Swallowing one is asking a demolition system to leave a small building alone.
Two barriers, in order. Enzymes in the stomach and small intestine cleave the chain. Then whatever survives has to cross the intestinal wall — and peptides are large and water-loving, which is exactly the wrong combination for passive absorption.
This is the reason peptide drugs are typically injected — and why each exception below needed engineering to exist.
One molecule, two routes, one label
Semaglutide is the cleanest case available, because the same label carries both forms.
As of August 2026 the label states that the absolute bioavailability of semaglutide following subcutaneous administration is 89%1.
The recommended maintenance dosage of the injection is 2.4 mg once weekly. The recommended maintenance dosage of the tablet is 25 mg orally once daily1.
Do the arithmetic. 25 mg a day is 175 mg a week. Against 2.4 mg a week injected, that is roughly 73 times the milligrams of the same molecule to arrive at a comparable therapeutic effect.
Almost all of that difference is what the gut destroys or refuses to absorb.
Our semaglutide page has the full approval and trial record.
What makes the tablet work at all
An absorption enhancer. The label lists salcaprozate sodium — SNAC — as an absorption enhancer in the tablets1.
It buys absorption at the cost of a strict administration routine. The label directs that the tablet be taken orally once daily on an empty stomach in the morning with water up to 4 ounces, not with other liquids; swallowed whole, not split, crushed, chewed or dissolved; and followed by a wait of at least 30 minutes before eating, drinking other beverages, or taking other oral medications1.
Every one of those instructions exists because absorption of this tablet is fragile enough that ordinary breakfast behaviour would change it.
The label says the two forms are not interchangeable
This is the part most easily lost in a summary.
The label notes that semaglutide blood concentrations after administration of the tablets are lower than after the 2.4 mg injection, that this may be associated with reductions in absolute bioavailability, and that variability in blood concentration is higher with the tablets1.
Higher variability means the same dose produces a wider spread of exposures across people, and potentially across days in the same person. That is a real pharmacological difference, not a footnote about convenience.
The label also carries a specific route-switching instruction for tolerability: if a patient does not tolerate the 25 mg once-daily maintenance dosage, it directs considering a switch to the 1.7 mg once-weekly injection1. That is the label acknowledging that these are different exposure profiles, not the same drug in a different wrapper.
What each route produced in trials
The tablet: OASIS 4 tested a 25 mg once-daily tablet in 307 participants and reported −13.6% at week 64 against −2.2% on placebo2.
The injection: STEP 1 tested 2.4 mg once weekly in 1,961 participants and reported −14.9% at week 68 against −2.4% on placebo3.
Those two numbers look close and they are not a comparison. Different trials, different durations, different populations, different estimands. A claim that the routes are equivalent needs a trial that randomised people between them, and the two figures above did not come from one.
The workaround that abandons the peptide entirely
The most interesting development in oral GLP-1 is not a better-absorbed peptide. It is not being a peptide.
Orforglipron is a small-molecule, nonpeptide oral GLP-1 receptor agonist4. Because it is not a peptide, the gut does not treat it as food, and the absorption-enhancer machinery is unnecessary.
Its phase 3 obesity trial randomised 3,127 patients to once-daily orforglipron at 6 mg, 12 mg or 36 mg or placebo for 72 weeks. Mean weight change at week 72 was −7.5%, −8.4% and −11.2% against −2.1% on placebo. Adverse events led to discontinuation in 5.3% to 10.3% of the orforglipron groups against 2.7% on placebo4.
This matters for reading the category: "oral GLP-1" now covers two chemically unrelated things. One is a peptide smuggled past the gut; one is a small molecule that does not have the problem. See what a peptide is for why that distinction keeps mattering.
What oral does not fix
Dose frequency. Getting past the gut does not extend a molecule's life once it is in — the tablet is daily and the injection weekly, on the same label1. Half-life, not route, sets frequency; see half-life and dosing frequency.
Side effects. In the oral semaglutide trial the most common adverse events were gastrointestinal, at 74.0% against 42.2% on placebo2. Orforglipron's phase 3 reported gastrointestinal effects as its most common adverse events too4. The nausea in this class is largely receptor-mediated, and the route does not remove the receptor.
Interchangeability. Two routes of the same molecule at doses 73-fold apart, with different exposure profiles and different variability, are two different products. The label treats them that way.
For the class-level picture, see incretins explained, and for goal-level comparisons, weight loss.
Frequently asked questions
Why do most peptides have to be injected?
The digestive system breaks proteins into amino acids, and a peptide is a short chain of amino acids. Enzymes cleave it in the stomach and small intestine, and whatever survives still has to cross the intestinal wall — which large, water-loving molecules do poorly. Injection skips both barriers.
How much bigger is the oral dose of the same peptide?
For semaglutide, roughly 73 times per week. The label lists a maintenance dosage of 25 mg orally once daily — 175 mg a week — against 2.4 mg once weekly by injection. The label also states that absolute bioavailability following subcutaneous administration is 89%.
Are the tablet and the injection the same thing?
The label treats them as distinct products. It notes that blood concentrations after the tablets are lower than after the 2.4 mg injection, that this may be associated with reduced absolute bioavailability, and that variability in concentration is higher with the tablets. It also gives a specific instruction to consider switching to the 1.7 mg weekly injection if the 25 mg daily tablet is not tolerated.
Why does the tablet have to be taken on an empty stomach?
Because its absorption depends on an enhancer, salcaprozate sodium, and is fragile enough that ordinary eating and drinking changes it. The label directs taking it once daily on an empty stomach in the morning with water up to 4 ounces, swallowing it whole, and waiting at least 30 minutes before food, other beverages or other oral medications.
Is orforglipron an oral peptide?
No. It is a small-molecule, nonpeptide GLP-1 receptor agonist, which is why it does not need an absorption enhancer. In its 3,127-patient phase 3 obesity trial, mean weight change at week 72 was −11.2% on the 36 mg dose against −2.1% on placebo.
Does taking a peptide orally reduce side effects?
Not in the published trials. The oral semaglutide trial reported gastrointestinal adverse events in 74.0% against 42.2% on placebo, and orforglipron's phase 3 reported gastrointestinal effects as its most common adverse events. The nausea in this class comes largely from receptor activation, which the route does not change.
References
- DailyMed, U.S. National Library of Medicine (2026). WEGOVY (semaglutide) injection, solution; WEGOVY (semaglutide) tablet — prescribing information. DailyMed Structured Product Label. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
- Wharton S, Lingvay I, Bogdanski P, et al. (2025). Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/40934115/
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Wharton S, Aronne LJ, Stefanski A, et al. (2025). Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/40960239/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.
Continue reading
Amylin Analogs: The Next Class After Incretins
An amylin analog has been FDA-approved since 2005. What changed is not the hormone — it is how long the molecule lasts. The trials, in order.
ReadCertificates of Analysis: What They Prove
A COA is a claim about a lot, not a guarantee about a vial. What each test answers, what a purity figure cannot say, and the gap the document never closes.
ReadCompounded Is Not the Trial Drug
A trial tests one defined article: a molecule, a form, a concentration, a container. Compounding changes some of those, and the evidence travels only that far.
Read503A vs 503B: What Is Actually in the Vial
One scheme is inspected against manufacturing standards; the other is not. What each may legally start from, and what the inspection record shows in practice.
ReadGrowth-Hormone Secretagogues: What the Evidence Actually Shows
These compounds reliably raise IGF-1. That is the surrogate. When trials measured function, fracture recovery or disease progression, the results changed.
ReadHealing Peptides and the Gap Between Anecdote and Trial
BPC-157 and TB-500 have thirty years of animal work and a very thin human record. Here is exactly what is registered, what is published, and what neither shows.
ReadHow to Read a ClinicalTrials.gov Record
A registration is a filing, not a review. Fifteen fields, two real peptide records, and the specific places where a record quietly tells you it has stalled.
ReadIncretins Explained: GLP-1, GIP and Glucagon
Three hormones, three receptors, and a class of drugs built on them. What each one does, and why the receptor diagram predicts less than it looks like.
ReadMuscle During Rapid Weight Loss: What Has Been Measured
Roughly a quarter of the weight lost is lean mass — and that was true on placebo too. What the DXA substudies actually show, and how small they are.
ReadOpen-Label vs Blinded: What You Can Conclude
Masking is not a quality score — it decides which explanations a trial can rule out. Five real registry records, and the honest evidence on blinding itself.
ReadHalf-Life and Dosing Frequency
From 1.5 minutes to a week, on labels for the same hormone family. Half-life is the number that decides whether a peptide is dosed before meals or once a month.
ReadReconstitution: The Arithmetic, Not the Advice
Concentration is mass divided by volume — except the naive division is wrong, and an FDA label's own numbers prove it. The maths, and what it cannot tell you.
ReadWhat a Phase 2 Result Does and Does Not Tell You
Phase 2 is a dose-finding experiment, not a verdict. Two peptide programmes where the phase 3 exists show exactly which parts of the number survive.
ReadRegistered but Never Reported: The Trials That Vanish
Completed trials that post no results are common and measurable. How to check a compound's registry file, and what the silence does and doesn't tell you.
ReadWhy n=30 Is Not the Same as n=3,000
Enrolment size is not a quality badge — it is precision, and it is the ability to see rare harm. Worked on real peptide trials, with the arithmetic shown.
ReadSurrogate Endpoints vs Outcomes That Matter
Most peptide claims rest on a marker moving, not on anything happening to a person. Two paired trials show what the difference costs to establish.
ReadWhy a Triple Agonist Is Not Simply Better Than a Dual
Adding a receptor adds a mechanism, a side-effect profile, and a reason a trial might read differently. The numbers do not rank the way the labels suggest.
ReadWhat a Peptide Is, and What the Word Hides
Three amino acids or sixty-three thousand daltons — both get called peptides. The definitional confusions that cause the most misreading, settled by labels.
ReadWhat “Research Chemical” Actually Means
The phrase is a sales category, not a regulatory one. What FDA has actually published about seventeen of these peptides, and what the label is doing instead.
ReadHow to Tell a Peptide Claim Is Outrunning Its Evidence
Twelve tells, each with a real case from the registry or the literature. Overstated peptide claims tend to fail on one of them, and usually the same one.
ReadWhat Happens When a Peptide Trial Fails
Four negative results, and what each one killed. A trial can fail an indication, a molecule, a surrogate, or nothing at all — and the difference matters.
ReadWho Funded the Trial, and Why It Matters
Sponsorship shifts conclusions more than it shifts methods. Where to find the funding line, what the Cochrane evidence measured, and what it did not.
ReadWhy Most Peptide Trials Are Small and Short
A registry census, August 2026: one compound has 759 registered studies, another has zero. The reasons are economic, not about whether the drug works.
Read